Pharmaceutical

AbbVie gains FDA approval for EPKINLY in follicular lymphoma

AbbVie has announced the receipt of accelerated approval from the US FDA for EPKINLY to treat adults with follicular lymphoma.

Jun 28, 2024 - 04:00
AbbVie gains FDA approval for EPKINLY in follicular lymphoma
AbbVie has announced the receipt of accelerated approval from the US FDA for EPKINLY to treat adults with follicular lymphoma.
Read the original article

Tags:

Previous Article

FDA issues complete response to Daiichi Sankyo-MSD’s BLA for NSCLC

Next Article

Unlocking brain health: The power of Cognizin® Citicoline revealed

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: The Q2 health tech tracker: 13 key industry events and milestones to watch

STAT+: The Q2 health tech tracker: 13 key industry even...

Apr 5, 2023

FDA greenlights first over-the-counter birth control pill

FDA greenlights first over-the-counter birth control pill

Jul 13, 2023

STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial

STAT+: Breast cancer drug from AstraZeneca, Daiichi hit...

Sep 22, 2023